generic indexcompaniesmedical actsmedicalcollege

Drug Improves Birth Rates for Women with Ovary Disorder

Polycystic ovary syndrome (PCOS) is a leading cause of female infertility. It affects 5-10% of reproductive-age women. Women with PCOS have unusually high levels of male hormones, infrequent or irregular menstruation cycles, and oftentimes enlarged ovaries packed with fluid-filled cysts.

The current treatment for PCOS infertility is the drug clomiphene. It works by blocking estrogen action, which stimulates hormones that induce ovulation. However, clomiphene has multiple side effects, including hot flashes and mood changes. The drug’s 22% success rate for live births is relatively low, and it tends to lead to a high number of twin or multiple pregnancies.

In a search for more effective ways to reverse PCOS infertility, some physicians have begun using the drug letrozole. Letrozol has been approved as a breast cancer treatment by the U.S. Food and Drug Administration. The drug is also known to suppress production of estrogen, which in turn triggers release of the hormones that drive ovulation.

A multicenter clinical study led by Dr. Richard S. Legro of Penn State College of Medicine compared the effectiveness of letrozole and clomiphene in treating PCOS-related infertility. The effort was funded in part by NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and National Center for Advancing Translational Sciences (NCATS). Results were published on July 10, 2014, in the New England Journal of Medicine.

The researchers enrolled 750 infertile women with PCOS who were between 18 and 40 years of age. All participants were attempting to achieve pregnancy, and their male partners met minimum sperm count requirements. The participants were randomly divided into 2 groups to receive either letrozole or clomiphene. Women were given up to 5 monthly cycle treatments.

The researchers found that women treated with letrozole were more likely to have live births than those receiving clomiphene (27.5% vs. 19.1%). Letrozole also led to significantly increased ovulation rates compared to clomiphene (61.7% vs. 48.3%). Although there was no statistical significance (a difference great enough to prove it wasn’t due to chance), letrozole treatment tended to result in fewer twin pregnancies compared to clomiphene therapy (3.4% vs. 7.4%). Side effects with letrozole were fatigue and dizziness, as opposed to the hot flashes and mood changes seen with clomiphene. Birth defect rates were similar in the 2 groups.

The findings suggest that letrozole is a promising alternative to clomiphene for treating PCOS infertility. Further study will be needed to clarify the long-term safety of the treatment.

“We are extremely encouraged that letrozole could provide a new, oral, first-line therapy for this common disorder,” Legro says. “A letrozole-based treatment potentially could provide a less invasive, less expensive therapy, with a lower risk of multiple pregnancy.”




Copyright ©2007-2018. medline india. All rights reserved.

Content on this web site is for informational purpose only. It is not intended to provide medical or other professional advice.